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Abstract Mesenchyme forkhead-1 (MFH-1), a winged helix/
forkhead transcription factor, is expressed in developing
cartilaginous tissues, kidney and arch arteries, and is essential
for the normal development of the axial skeleton and aortic arch
formation of mice. To investigate the possible role of MFH-1 in
osteogenesis and osteoblast differentiation, we examined expres-
sion of MFH-1 induced by bone morphogenetic protein-2 (BMP-
2) in C2C12 myoblasts, and found that MFH-1 protein and also
MFH-1 mRNA increased markedly in C2C12 cells after
treatment with BMP-2. To confirm the hypothesis that BMP-2
induced osteoblastic differentiation of C2C12 cells by increasing
MFH-1 expression, we lowered the endogenous MFH-1 level by
stably transfecting C2C12 cells with antisense MFH-1 sequence,
and found that in antisense MFH-1 cell lines, both alkaline
phosphatase (ALP) activity and production of osteocalcin
induced by BMP-2 decreased markedly in comparison with
control cell lines. Our results suggest that the BMP-2-induced
MFH-1 protein may play a key role in regulating the
commitment to osteoblastic differentiation of C2C12 myoblasts
and production of osteoblast markers including ALP and
osteocalcin.
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1. Introduction
Bone morphogenic protein-2 (BMP-2), a prototype of the
BMP subgroup [1], promotes the development of bone and
cartilage by inducing the di¡erentiation of multipotent mes-
enchymal progenitor cells into osteoblastic cells or cartilage
cells, respectively. Recombinant BMP-2 not only stimulates
the osteoblastic maturation of the osteoblast progenitor
ROB-C26 cells [2] and human neonatal calvaria cells [3], but
also induces non-osteoblast cells, such as pluripotent ¢bro-
blastic cell lines, C3H10T1/2 [4], bone marrow stromal cell
lines, W-20-17 [5], ST2 and MC3T3-G/PA6 cell lines [6] to
di¡erentiate into osteoblasts, as assessed by induction of alka-
line phosphatase (ALP) activity and expression of osteocalcin
[2^6].
C2C12 myoblasts can generate multinucleated myotubes
when they are cultured in low-mitogen medium [7]. However,
under the same condition, formation of myotubes could be
inhibited by adding BMP-2 to the medium, which converted
the di¡erentiation pathway to the osteoblast lineage [7]. Thus,
BMP-2-induced osteogenesis of C2C12 cells provides a useful
experimental model for investigating the molecular mecha-
nism of osteogenesis in vitro in culture systems. Recent studies
have demonstrated that cytoplasmic Smad proteins are in-
volved in the processes of inhibition of myoblastic di¡erentia-
tion and induction of osteoblast di¡erentiation [8,9]. The ef-
fects of BMP-2 are mediated through BMP receptor IA
(BMPRIA), and activation of BMPRIA causes phosphory-
lation of Smad5 to subsequently form a complex with
DPC4 (Smad4) and this complex is then translocated to the
nucleus. When Smads are transiently transfected into C2C12
cells, both Smad1 and Smad5 induce ALP activity and de-
crease the activity of the myogenic promoter without BMP-
2 [9].
Mesenchyme forkhead-1 (MFH-1) protein is a member of
the winged helix/forkhead transcription factors. We have iso-
lated it as a 62-kDa protein [10], and identi¢ed its expression
in developing cartilaginous tissues, kidney and arch arteries of
mice [11^13]. Mice de¢cient in MFH-1 gene display defective
formation in the aortic arches, multiple craniofacial bones and
vertebral column, thus implying that it plays an essential role
in the normal development of the axial skeleton and aortic
arch formation [12,14,15]. However, it is still unknown how
this transcriptional factor functions in the regulated prolifer-
ation, survival and di¡erentiation of the cell. In the present
study, we investigated the role of MFH-1 protein in the in
vitro osteogenic pathway, and found that MFH-1 responded
to BMP-2 and subsequently promoted osteoblastic di¡erentia-
tion of C2C12 myoblasts.
2. Materials and methods
2.1. Plasmid construction
The NotI/EcoRI fragment of MFH-1 cDNA [11] was ¢lled in, li-
gated with the EcoRI linker and inserted into the EcoRI-cut pGEX-
2T to make the GST-MFH-1 plasmid. The CX-MFH-1 plasmid was
described previously [10]. The CX-MFH-1 antisense (as) plasmid was
made by introducing the EcoRI fragment of the CX-MFH-1 plasmid
into the EcoRI site of the CX-N2 vector [10] and selecting the anti-
sense orientation.
2.2. Production of anti-mouse MFH-1 monoclonal antibody
The GST-MFH-1 plasmid was transformed in Escherichia coli LE
392. After induction with 0.5^1.0 mM isopropyl L-D-thiogalactopyr-
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anoside, the bacterial lysates were prepared and applied to gluta-
thione-Sepharose 4B (Pharmacia Biotech, Sweden). Washing and elu-
tion of the GST-MFH-1 protein (amino acids 290^494) were per-
formed according to the supplier’s directions. Puri¢ed GST-MFH-1
protein was used to immunize Wistar rats. After 3 days of boosters,
isolated spleen cells were fused with P3U1 myeloma cells using poly-
ethylene glycol 4000 (Nakarai Tesque Inc., Tokyo, Japan), as de-
scribed elsewhere [16]. Hybridoma cells secreting anti-MFH-1 anti-
body were isolated and cloned by immunostaining the CX-MFH-1
gene-transfected L cells with culture supernatants. Cloned anti-
MFH-1 hybridoma cell lines were injected into the abdomen of pris-
tane-treated nude mice to obtain ascites. Monoclonal anti-MFH-1
antibody was puri¢ed from ascites using protein A-Sepharose 4B
(Pharmacia).
2.3. Cell culture and transfection
The mouse myoblast C2C12 cells and L cells were obtained from
the RIKEN Cell Bank (Tsukuba, Japan) and cultured in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) (Sigma Chemical Co., St. Louis,
MO, USA) containing 10% fetal calf serum (FCS). Human bladder
carcinoma HTB9 cells were maintained in RPMI 1640 (Bio-Rad)
containing 10% FCS. To examine the e¡ects of BMP-2 and trans-
forming growth factor-L (TGF-L), C2C12 cells were inoculated in
12-well tissue culture plates at a density of 2U104 cells per cm2. After
overnight incubation, the medium was replaced with DMEM contain-
ing 5% FCS and 300 ng/ml of BMP-2 or 10 ng/ml of TGF-L, and then
the cells were cultured for 0.5, 1, 2, 3 and 6 days. For antisense
studies, 20 Wg of CX-MFH-1(as) plasmid and CX-N2 empty vector
as control were transfected into cultured C2C12 cells using the cal-
cium phosphate precipitation method [17]. Forty-eight hours after
transfection, the medium was replaced with DMEM containing 400
Wg/ml G418 (Gibco/BRL) for 3 weeks. Three antisense clonal cell lines
(named AS 7, AS 20 and AS 23) and two control clonal cell lines
(named V 14 and V 16) were established.
2.4. Western blot analysis
Cells were solubilized in RIPA lysis bu¡er (50 mM Tris^HCl, pH
6.8, 0.1% sodium dodecyl sulfate (SDS), 150 mM NaCl, 1% Nonidet
P-40, 0.5% sodium deoxycholate, 1 mM dithiothreitol and 2 mM
phenylmethylsulfonyl £uoride). The lysates were separated by SDS^
PAGE and transferred to Immobilon polyvinylidene di£uoride
(PVDF) membranes (Millipore) [18]. Immunoblotting with anti-
mouse MFH-1 monoclonal antibody (1:1000) was carried out. The
proteins were visualized with horseradish peroxidase-conjugated swine
anti-rat IgG antibody (Dako, Glostrup, Denmark), and enhanced by
the ECL detection kit (Amersham, Buckinghamshire, UK).
2.5. RNA isolation and Northern blot analysis
Total RNA was isolated from C2C12 cells treated with BMP-2 (300
ng/ml) for 2 days by the guanidine thiocyanate and cesium chloride
ultracentrifugation extraction method. For Northern hybridization,
total RNA (12 Wg) was electrophoresed in 1.2% agarose gels contain-
ing 2.2 M formaldehyde, and blotted to GeneScreen Plus Hybridiza-
tion Transfer Membrane (NEN Life Science, Billerica, MA, USA).
The 1.1-kb NotI/EcoRI fragment of mouse MFH-1 cDNA was la-
beled with [32P]dCTP (Amersham Pharmacia Biotech, Buckingham-
shire, UK) using the random primer technique (Multiprime DNA
Labeling Systems, Amersham Pharmacia Biotech). Hybridization
was performed in a solution containing 5USSPE, 50% (w/v) deionized
formamide, 5UDenhardt’s solution, 1% SDS, 10% dextran sulfate
(MW 500 000) and 10 Wg/ml of denatured salmon sperm DNA at
42‡C overnight. The hybridized probe was removed by boiling in
0.1USSPE, 50% formamide and 0.1% SDS for 1 h at 65‡C. The
amounts of mRNA were veri¢ed by rehybridizing the ¢lter with elon-
gation factor-1 (EF-1K) cDNA [19] probe, and the signals were de-
tected by autoradiography.
2.6. ALP activity assay
ALP activity in the cell lysate was measured as described by Kata-
giri et al. [7]. The enzyme activity was expressed as nmol of p-nitro-
phenol produced per min per mg of protein.
2.7. Quantitation of osteocalcin production
The amount of osteocalcin secreted into the culture medium was
measured by radioimmunoassay (RIA) using a mouse osteocalcin as-
say kit (Biomedical Technologies Inc., Stoughton, MA, USA).
2.8. Immuno£uorescent analysis
The cells were seeded on coverslips in 24-well plates. On the next
day, the cells were ¢xed and immuno£uorescently stained with anti-
mouse MFH-1 monoclonal antibody (1:1000), and FITC-conjugated
anti-rat IgG antibody (Dako) was used as the secondary antibody, as
described previously [20].
3. Results
3.1. MFH-1 protein was detected speci¢cally by monoclonal
antibody
To study the role of MFH-1 protein, we produced anti-
mouse MFH-1 monoclonal antibody. We transfected the
CX-MFH-1 plasmid and CX-N2 empty vector into human
bladder carcinoma HTB9 cells. Two days after transfection,
the cell lysates were processed for Western blot analysis. In
the HTB9 cells transiently transfected with MFH-1 gene, a 62-
kDa band was detected with the anti-mouse MFH-1 antibody
(Fig. 1A, lane 2). No signals were detected in cells transfected
with the control vector (Fig. 1A, lane 1). In addition, immu-
no£uorescent staining with anti-mouse MFH-1 antibody
showed that overexpressed MFH-1 protein was present in
the nucleus of the transfected cells (Fig. 1B, b) and endoge-
nous MFH-1 protein was detected in the mouse myoblast
C2C12 cells (Fig. 1B, c). These results indicated that our anti-
body speci¢cally recognized the mouse MFH-1 protein.
Fig. 1. A: Western blot analysis of MFH-1 protein in transfected
cells with monoclonal antibody. HTB9 cells were transfected with
20 Wg of CX-MFH-1 (lane 2) plasmid and CX-N2 empty vector
(lane 1). Two days after the transfection, the cells were solubilized
in RIPA lysis bu¡er. Equivalent amounts of lysates (20 Wg) were
subjected to SDS^PAGE (10% gel) and transferred to a PVDF
membrane, which was immunoblotted with anti-mouse MFH-1
monoclonal antibody. B: Expression of MFH-1 proteins in cultured
cell lines. L cells transfected with CX-N2 empty vector (a) and CX-
MFH-1 gene (b), and C2C12 cells (c) were ¢xed and immunostained
with anti-mouse MFH-1 monoclonal antibody, followed by incuba-
tion with FITC-conjugated anti-rat IgG antibody. Magni¢cation:
U490.
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3.2. BMP-2-induced expression of MFH-1 protein in
C2C12 cells
We examined the relationship between the expression of
MFH-1 protein and osteogenesis by BMP-2 in C2C12 cells.
First, we determined the basal expression of MFH-1 protein
in C2C12 cells. MFH-1 protein was constitutively expressed in
C2C12 cells (Fig. 2A, lane 3 and Fig. 1B, c), and its mobility
was the same as that for HTB9 cells transfected with the CX-
MFH-1 expression plasmid (Fig. 2A, lane 2). Then, we exam-
ined the time course of the expression level of MFH-1 protein
in C2C12 cells after BMP-2 treatment. After replating C2C12
cells in the absence of BMP-2, the expression of MFH-1 pro-
tein was increased in 0.5 and 1 day and then decreased grad-
ually from 2 to 6 days (Fig. 2B, lanes 1, 3, 5, 7 and 9),
However, when C2C12 cells were treated with BMP-2, the
MFH-1 protein sustained prominently higher levels from 12
h to 6 days in comparison with untreated cells (Fig. 2B, lanes
2, 4, 6, 8 and 10). In contrast, in C2C12 cells treated with
TGF-L, a short-term slight increase of MFH-1 protein was
detected in 12^24 h (Fig. 2C). These results suggest that
MFH-1 may be a target for the BMP-2 signaling pathway
in C2C12 cells, and may mediate the e¡ects of BMP-2 in
promoting the osteogenic di¡erentiation pathway in C2C12
myoblasts.
3.3. Expression of MFH-1 mRNA was induced by BMP-2 in
C2C12 cells
Given the marked enhancement of the MFH-1 protein level
by BMP-2 in C2C12 cells, we next determined whether this
increase might re£ect changes in the MFH-1 mRNA level. By
Northern blot analysis of total RNA from C2C12 cells after
2 days of incubation with low-mitogen medium containing
300 ng/ml of BMP-2 or lacking BMP-2, MFH-1 mRNA
was detected as a weak band of 3.0 kb in the BMP-2-un-
treated cells (Fig. 3A, lane 1), but was enhanced dramatically
in the BMP-2-treated cells (Fig. 3A, lane 2), which showed an
approximately eight-fold higher level than in the untreated
cells (Fig. 3B). This result suggests that BMP-2-induced up-
regulation of MFH-1 occurred at the pretranslational level.
3.4. Decreasing MFH-1 level by transfection of antisense
MFH-1-inhibited osteoblastic di¡erentiation of
C2C12 cells
Our results demonstrated that BMP-2 markedly enhanced
MFH-1 mRNA and protein levels in C2C12 cells. We hy-
pothesized that if BMP-2-induced MFH-1 plays a key role
in promoting osteoblastic di¡erentiation from C2C12 cells, a
lowered MFH-1 level by transfection of the antisense MFH-1
sequence would block the e¡ects of BMP-2, and thereby, the
osteoblastic di¡erentiation of C2C12 cells would be inhibited.
To address this issue, we transfected C2C12 cells with the
antisense MFH-1 expression construct, CX-MFH-1(as). After
Fig. 2. E¡ects of BMP-2 and TGF-L on MFH-1 protein levels in
C2C12 cells. A: Basal expression of MFH-1 protein in cultured
C2C12 cells. HTB9 cells transfected with the CX-N2 empty vector
(lane 1) and CX-MFH-1 gene (lane 2) and C2C12 cells (lane 3)
were cultured in medium containing 10% FCS. 20 Wg of lysates
from transfected cells and 50 Wg of lysates from C2C12 cells were
analyzed by Western blot as described in Fig. 1A. B and C: C2C12
cells were inoculated in 12-well tissue culture plates at a density of
2U104 cells/cm2. After overnight incubation, the medium was re-
placed with DMEM containing 5% FCS in the absence (3) or pres-
ence (+) of BMP-2 (300 ng/ml) (B) and TGF-L (10 ng/ml) (C) for
the indicated times. The cells were solubilized in lysis bu¡er and the
MFH-1 protein levels were determined by Western blot analysis (50
Wg of lysates/lane) with anti-mouse MFH-1 monoclonal antibody.
Fig. 3. E¡ect of BMP-2 on expression of MFH-1 mRNA in C2C12
cells. A: Northern blot analysis of total RNA from C2C12 cells.
The cells were cultured in DMEM containing 5% FCS in the ab-
sence (lane 1) and presence of 300 ng/ml of BMP-2 (lane 2) for
2 days. Total RNA from each culture (12 Wg) was analyzed by
Northern blotting using a 32P-labeled mouse MFH-1 cDNA probe.
The same blot was reprobed with elongation factor-1 (EF-1K)
cDNA to assess the quantity of RNA (bottom). B: The levels of
MFH-1 mRNA expression were quanti¢ed using NIH Image soft-
ware and normalized to the EF-1K levels. The values are expressed
as arbitrary units.
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selection of stable clones, three independent lines of antisense
cells (named AS 7, AS 20 and AS 23) showed a marked
reduction in endogenous MFH-1 protein level by Western
blot analysis (Fig. 4A, lanes 4 and 5 and data not shown).
The expression level of the MFH-1 protein in C2C12 cells
transfected with an empty vector (named V 14 and V 16)
was the same as that of the parental C2C12 cells (Fig. 4A,
lanes 1^3). Next, we investigated the expression levels of
MFH-1 protein in antisense cells after BMP-2 treatment,
and found that the MFH-1 expression in antisense cell lines
(Fig. 4B, lanes 8 and 10) was lower than those in the control
cell lines (Fig. 4B, lanes 4 and 6) and parental C2C12 cells
(Fig. 4B, lane 2). This result suggests that antisense MFH-1
gene would inhibit the expression of the MFH-1 protein after
treatment with BMP-2.
Finally, we examined whether reducing the MFH-1 levels
would inhibit the osteoblastic di¡erentiation of C2C12 cells.
ALP activity and production of osteocalcin, which are well
known markers of the osteoblast lineage, were measured in
control cells and antisense cells cultured in low-mitogen me-
dium containing 300 ng/ml of BMP-2 for 1, 3 and 6 days. As
shown in Fig. 4C,D, in the control cell line V 16, ALP activity
and production of osteocalcin were detected from 1 day after
BMP-2 treatment, and then markedly increased from 3 days
onwards. In contrast, in both the antisense cell lines AS 7 and
AS 20, ALP activity was lower than that of the control cells
(Fig. 4C), and almost no production of osteocalcin was de-
tected until day 6 (Fig. 4D). Also, ALP activity and produc-
tion of osteocalcin were not detected in untreated cells over
the 6-day period examined (data not shown). This means that
a lowered level of MFH-1 inhibits the BMP-2-induced ALP
activity and production of osteocalcin in antisense cells. These
results suggest that the MFH-1 protein may mediate osteo-
blastic di¡erentiation of C2C12 cells by BMP-2.
Fig. 4. Antisense MFH-1 inhibited osteoblastic di¡erentiation of C2C12 cells. A: Antisense MFH-1 attenuated the expression of endogenous
MFH-1 protein. C2C12 cells (lane 1), control cell lines (lanes 2 and 3) and antisense cell lines (lanes 4 and 5) were seeded in a 6-cm tissue cul-
ture plate at a density of 5U104 cells/cm2 and cultured in DMEM containing 10% FCS. On the next day, cells were harvested and MFH-1
protein levels were determined by Western blot analysis (50 Wg of lysates/lane). B: Antisense MFH-1 inhibited the BMP-2-induced expression
of MFH-1 protein. C2C12 cells (lanes 1 and 2), control cell lines (lanes 3^6) and antisense cell lines (lanes 7^10) were cultured in DMEM con-
taining 5% FCS in the absence (lanes 1, 3, 5, 7 and 9) and presence of 300 ng/ml of BMP-2 (lanes 2, 4, 6, 8 and 10) for 2 days. MFH-1 pro-
tein levels were determined by Western blot analysis (50 Wg of lysates/lane). C and D: Antisense MFH-1 inhibited BMP-2-induced ALP activity
and osteocalcin production in C2C12 cells. The control cell line (V 16, closed circles) and the antisense cell lines (AS 7, open circles and AS
20, open squares) were seeded in 12-well tissue culture plates at a density of 2U104 cells/cm2 and cultured in DMEM containing 10% FCS.
After overnight incubation, the medium was replaced with DMEM containing 5% FCS and 300 ng/ml of BMP-2 for the indicated times. The
ALP activity of the cell lysate was measured using p-nitrophenyl phosphate as a substrate. The unit of ALP activity is nmol of p-nitrophenol
formed per mg of protein per min (C). The amounts of osteocalcin secreted into the culture medium were determined by RIA (D). Values are
the means þ S.D. of three individual experiments.
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4. Discussion
In this study, we found that BMP-2 induced a sustained
increase of MFH-1 expression during C2C12 myoblast trans-
di¡erentiation to osteoblast lineage. Furthermore, lowering
the endogenous MFH-1 level by stably transfecting C2C12
cells with antisense MFH-1 markedly decreased ALP activity
and inhibited production of osteocalcin in the presence of
BMP-2. These ¢ndings suggest that the MFH-1 protein re-
sponse to BMP-2 signaling contributes to the osteoblast dif-
ferentiation of C2C12 cells.
The MFH-1 gene is expressed in developing vertebrae, car-
tilaginous tissues, kidney and arch arteries of mice [11^13].
We examined more than 20 cultured cell lines and found
that MFH-1 protein was expressed in human bone, cartilage,
blood vessel and nephroblast cell lines, and also in mesenchy-
mal progenitor cells such as C2C12 cells and bone marrow
stromal ST2 cells of mice (Fig. 1 and data not shown). These
results indicate that the expression of MFH-1 in vitro in cul-
tured cell lines corresponds well to that in mice embryos. In
vitro studies using these cultured cells may clarify the di¡er-
entiation process in embryos. In MFH-1-de¢cient mice, defec-
tive formation of skeleton and aortic arches was observed
[12,14,15]. The defects of skeletogenesis were mainly observed
in the craniofacial bones and vertebral column [12,15], imply-
ing that MFH-1 plays an essential role in the normal develop-
ment of the axial skeleton and skull of mice. Thus, we are
interested in investigating the possible roles of MFH-1 in
skeletogenesis and osteoblast di¡erentiation in culture sys-
tems.
It is well known that BMP-2 not only induces the osteo-
genesis of osteoblast and multipotent mesenchymal progenitor
cells, but also converts the di¡erentiation pathway of C2C12
myoblasts into the osteoblast lineage [7]. We found that
MFH-1 was expressed in C2C12 cells, and its expression grad-
ually decreased after 2 days of culture in low-mitogen me-
dium, and only a very weak band was detected at 6 days
(Fig. 2B,C, lanes 1, 3, 5, 7 and 9). However, in BMP-2-treated
cells, the MFH-1 protein expression displayed sustained in-
creased levels from 12 h to 6 days in comparison with un-
treated cells (Fig. 2B). In contrast, a short-term slight increase
of MFH-1 protein was found in 12^24 h with TGF-L treat-
ment (Fig. 2C), which is consistent with the fact that neither
an increase of ALP activity nor production of osteocalcin was
found in TGF-L-treated C2C12 cells [7,8]. This result indicates
that di¡erent pathways may exist for the e¡ects of BMP-2 and
TGF-L in C2C12 cells. Our results strongly support the idea
that MFH-1 responds to the BMP-2 signaling pathway in
C2C12 cells and promotes the osteoblastic fate. The possibil-
ity that MFH-1 might respond to TGF-L to favor other cell
fates in another di¡erentiation system could not be excluded.
We hypothesized that MFH-1 protein might play a key role
in the BMP-2-mediated commitment to osteoblastic di¡eren-
tiation of C2C12 myoblasts. As demonstrated in Fig. 4C,D,
ALP activity decreased dramatically and only a trace amount
of osteocalcin production was detected in antisense MFH-1
cells, in which the endogenous MFH-1 level was lowered. This
suggests that BMP-2-induced MFH-1 protein may regulate
the osteoblast di¡erentiation of C2C12 cells and the synthesis
of osteoblast markers.
We have no direct evidence for the involvement of MFH-1
in myogenic di¡erentiation from the C2C12 cells. However, it
has been reported that myotubes were ¢rst detected on day 3
and increased in number until day 6 in the low-mitogen me-
dium [7]. Under the same culture condition, our present re-
sults showed that expression of MFH-1 was decreased obvi-
ously on day 2, and only a minimal amount of MFH protein
was detected on day 6 (Fig. 2B, lanes 1, 3, 5, 7 and 9). These
results indicated that MFH-1 might have an inhibitory e¡ect
on myogenic di¡erentiation of the myoblasts.
Little is known about the molecular mechanism that MFH-
1 is induced with BMP-2 signaling. A current study on the
BMP-2 signaling pathway in C2C12 cells demonstrated that,
as in the case of BMPs, BMP-2 exerts its diverse biological
e¡ects through two types of transmembrane receptors, BMP
type I (BMPRI) and BMP type II (BMPRII) receptors [21].
BMPRI is further subclassi¢ed into BMPRIA and BMPRIB
[21]. The e¡ects of BMP-2 are mediated through BMPRIA in
C2C12 cells [8,9]. This signal causes phosphorylation of cyto-
plasmic Smad1 protein as well as Smad5 protein, and forms a
complex with Smad4, and then translocates to the nucleus
[8,9]. The functions of Smads are known to be associated
with various nuclear transcription factors that bind to the
speci¢c DNA sequence. Mix.2, an activin-responsive gene, is
involved in the early frog embryogenesis [22]. By analysis of
the Mix.2 promoter, it has been clari¢ed that FAST-1, a
winged helix transcription factor, forms a complex with
Smad2 and Smad4, and then binds to DNA [23]. The binding
regions of FAST-1 protein to Smad2 and Smad4 have been
determined [24]. We compared the amino acid sequences of
the Smad-associating regions of FAST-1 protein and that of
MFH-1 protein and could not ¢nd any homologous sequences
in the MFH-1 protein. Taken together with the ¢nding that
MFH-1 responds to BMP-2, it is not likely that MFH-1
works cooperatively with Smads like FAST-1, but might be
a downstream gene of the BMP-2/Smad signal pathway. In
order to understand the molecular mechanism that MFH-1
mediates osteoblastic di¡erentiation, the target genes that
MFH-1 regulates must also be determined in the future.
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